INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

被引：1
|
作者：
Mursleen, S. [1 ]
Shah, D. [2 ]
Schroeder, M. [3 ]
Perdrizet, J. [2 ]
Ndirangu, K. [2 ]
Risebrough, N. [4 ]
Martin, A. [5 ]
机构：
[1] GSK, Mississauga, ON, Canada
[2] ICON Hlth Econ, New York, NY USA
[3] GSK, Brentford, England
[4] ICON, ICON Hlth Econ, Toronto, ON, Canada
[5] GSK, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2438
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS44
引用
收藏
页码：S411 / S411
页数：1
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) IN COPD USING THE IMPACT TRIAL: CHINA MEDICAL INSURANCE SYSTEM PERSPECTIVE
    Wang, X.
    Martin, A.
    Cai, R.
    Tang, Z.
    Bointon, D.
    Noorduyn, S. G.
    Sun, A.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S169 - S169
  • [12] FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial
    Singh, Dave
    Barnhart, Frank
    Brealey, Noushin
    Criner, Gerard
    Dransfield, Mark
    Halpin, David M. G.
    Han, Meilan K.
    Jones, C. Elaine
    Kilbride, Sally
    Lange, Peter
    Lomas, David A.
    Martinez, Fernando J.
    Mouneimne, Dalal
    Wise, Robert
    Lipson, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [13] Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial
    Lipson, D. A.
    Barnhart, F.
    Brealey, N.
    Day, N. C.
    Brooks, J.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M.
    Han, M. K.
    Jones, C.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Singh, D.
    Tabberer, M.
    Wise, R. A.
    Pascoe, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [14] TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY
    Wise, Robert
    Van Der Valk, Ralf
    Hilton, Emma
    Criner, Gerard
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Kilbride, Sally
    Lange, Peter
    Martinez, Fernando
    Singh, Dave
    Lipson, David
    CHEST, 2018, 154 (04) : 729A - 731A
  • [15] COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) IN COPD USING THE FULFIL TRIAL: CHINA MEDICAL INSURANCE SYSTEM PERSPECTIVE
    Noorduyn, S. G.
    Wang, X.
    Martin, A.
    Cai, R.
    Tang, Z.
    Bointon, D.
    Sun, A.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S70 - S70
  • [16] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UMEC/VI FOR THE TREATMENT OF COPD PATIENTS IN COLOMBIA
    Gamboa Garay, O. A.
    Medina Torres, Y. A.
    Gamboa Garay, C. A.
    Bastidas Goyes, A. R.
    Dieleman, S.
    VALUE IN HEALTH, 2017, 20 (05) : A201 - A201
  • [17] COPD EXACERBATIONS IN PATIENTS SWITCHED FROM MULTIPLE-INHALER TRIPLE THERAPY TO FF/UMEC/VI
    Bogart, Michael
    Ismaila, Afisi
    Bangalore, Mohan
    Bunner, Scott
    Bengtson, Lindsay
    CHEST, 2021, 160 (04) : 1830A - 1830A
  • [18] Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
    Marin, Jose M.
    Mateos, Luis
    Roldan, Juan
    Echave-Sustaeta, Jose M.
    Pascual-Guardia, Sergi
    Pardo, Maria V.
    Velasco, Beatriz
    Jones, C. Elaine
    Kilbride, Sally
    Lipson, David A.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [19] COPD Exacerbations in Patients Switched from Multiple-Inhaler Triple Therapy to FF/UMEC/VI
    Beeh, K. M.
    Bogart, M.
    Ismaila, A. S.
    Bangalore, M.
    Bengtson, L. G. S.
    Brunner, S.
    INTERNIST, 2022, 63 (SUPPL 3): : 354 - 355
  • [20] Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
    Kendall, Robyn
    Martin, Alan A.
    Shah, Dhvani
    Shukla, Soham
    Compton, Chris
    Ismaila, Afisi S.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 1815 - 1825
12345